TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31539075
Drug: Antiangiogenic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiogenic agents
Study: 31539075
Drug: Anti-epidermal growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-epidermal growth factor receptor agents
Study: 12230317
Drug: Phytochemicals (plant-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytochemicals (plant-based compounds)
Study: 8522641
Drug: Single 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 50 mg, 100 mg, and 200 mg oral doses of nefazodone hydrochloride
Study: 8522641
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily doses of 50 mg, 100 mg, and 200 mg of nefazodone hydrochloride for 7.5 days
Study: 28452101
Drug: Combined low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined low-dose spironolactone plus vitamin E
Study: 28452101
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E monotherapy
Study: 25824210
Drug: Posaconazole 300
Normalized name: posaconazole 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole 300 mg in tablet form with a high-fat meal
Study: 25824210
Drug: Posaconazole 300
Normalized name: posaconazole 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole 300 mg in tablet form in fasted state
Study: 25824210
Drug: Posaconazole oral
Normalized name: posaconazole Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole oral suspension with a high-fat meal
Study: 23720786
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (0.05 mg/kg recombinant human GH daily)
Study: 18072840
Drug: Intensive smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive smoking cessation intervention (three 1-hr counseling sessions plus 8 weeks of nicotine patch therapy)
Study: 16294458
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta‐E2/0.25 mg TMG
Study: 16353319
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta‐E2/0.125 mg TMG
Study: 16294458
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2V/1 mg NET
Study: 12478329
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg once daily
Study: 12478329
Drug: Amoxicillin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1,000 mg three times a day
Study: 12478329
Drug: Amoxicillin (subset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (subset analysis)
Study: 9890248
Drug: Nonteratogenic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonteratogenic antibiotics (Control)
Study: 2478340
Drug: 53.3 g
Normalized name: ALCOHOL 53.3 g in 100 mL TOPICAL LIQUID [Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 53.3 g albumin as part of blood replacement therapy, followed by 20 g albumin daily for the first three postoperative days
Study: 29135370
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose of Ribavirin (ADJ)
Study: 29135370
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of Ribavirin (STD)
Study: 28601497
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral antipsychotics
Study: 20115934
Drug: Standard antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antidiabetic treatment
Study: 14760265
Drug: Milk-specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-specific IgE <2 kU/L
Study: 14760265
Drug: Milk-specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-specific IgE >=2 kU/L
Study: 7970937
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) administration (1 microgram/kg i.v. bolus)
Study: 7970937
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) administration
Study: 7970937
Drug: Metyrapone administration
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metyrapone administration (450 mg/m2/dose every 4 h x seven doses)
Study: 12843168
Drug: Metyrapone administration
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metyrapone administration
Study: 3301758
Drug: Misonidazole (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole (2.0 gm/m2/wk X 6 doses) with altered fractionation (2.5 Gy in a.m., 2.1 Gy in p.m.)
Study: 3301758
Drug: Misonidazole (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole (2.0 gm/m2/wk X 6 doses)
Study: 28701205
Drug: Art therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art therapy
Study: 30313053
Drug: Esmolol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.5 mg/kg bolus followed by infusion of 5 to 15 μg/kg/min)
Study: 20923446
Drug: Topical Aloe
Normalized name: Alo Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Aloe vera (AV) 0.4 ml (70% concentration) three times a day
Study: 20923446
Drug: Topical Aloe
Normalized name: Alo Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Aloe vera (AV)
Study: 17260222
Drug: Regime B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regime B: loading dose of 600 microg, followed by 200 microg every 3 h
Study: 14659328
Drug: epirubicin/vinorelbine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin/vinorelbine and sequential paclitaxel (EV/T)
Study: 14659328
Drug: epirubicin/cyclophosphamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin/cyclophosphamide plus sequential paclitaxel (EC/T)
Study: 8829944
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with diamorphine (2 mg initial dose, 0.2 mg h-1 background infusion, 0.2 mg on-demand doses with a 15 min lockout)
Study: 29497279
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg eletriptan HBr
Study: 29497279
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg eletriptan HBr
Study: 29497279
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg eletriptan HBr
Study: 29497279
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg eletriptan HBr (repeated oral dose 2 h apart)
Study: 24281285
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy protocol (5 sessions)
Study: 24281285
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy protocol
Study: 22571284
Drug: Total knee
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total knee arthroplasty (TKA) in addition to optimised non-surgical treatment
Study: 22571284
Drug: Optimised non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised non-surgical treatment alone
Study: 19248130
Drug: Step-up combination
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up combination therapy
Study: 20472597
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination with prednisone
Study: 20472597
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination with infliximab
Study: 10374215
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.625 mg/day with norgestrel 0.15 mg/day
Study: 7065478
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline (2.5-5.0 mg)
Study: 30816637
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg by mouth daily
Study: 25837634
Drug: G‐eCPD module
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐eCPD module (n = 80)
Study: 19476985
Drug: Low-dose, slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, slow-release transdermal glyceryl trinitrate (GTN) patch
Study: 19476985
Drug: Matched control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched control group (no immediate treatment for PSA recurrence)
Study: 19476985
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (GTN)
Study: 14993623
Drug: Sulfadoxine/pyrimethamine (SP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine/pyrimethamine (SP) - 25 mg/kg of sulfadoxine and 1.25 mg/kg of pyrimethamine
Study: 14993623
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) - 25 mg/kg
Study: 15570192
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (10 mg) methamphetamine hydrochloride
Study: 15570192
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (20 mg) methamphetamine hydrochloride
Study: 15570192
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (10 mg and 20 mg)
Study: 7572649
Drug: Intravenous dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dipyridamole (0.7 to 0.8 mg/kg) stress testing (Dip)
Study: 7572649
Drug: Dipyridamole (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (0.7 to 0.8 mg/kg) plus nonlimited exercise stress testing (Dip+Ex)
Study: 7572649
Drug: Dipyridamole (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (0.7 to 0.8 mg/kg) stress testing (Dip)
Study: 2149285
Drug: Toremifene 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 240 mg daily
Study: 2149285
Drug: Toremifene 60
Normalized name: toremifene 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 60 mg daily
Study: 2149285
Drug: Tamoxifen 20-40
Normalized name: tamoxifen 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20-40 mg daily
Study: 7015988
Drug: sotalol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol (80 mg b.i.d.)
Study: 7015988
Drug: atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50 mg b.i.d.)
Study: 7015988
Drug: sotalol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol + prazosin (3-5 mg b.i.d.)
Study: 7015988
Drug: atenolol +
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atenolol + prazosin (3-5 mg b.i.d.)
Study: 7015988
Drug: prazosin (3-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: prazosin (3-5 mg b.i.d.) alone
Study: 20648212
Drug: Lumbar interlaminar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumbar interlaminar epidural injections
Study: 17296625
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy for ventricular tachyarrhythmias
Study: 7654893
Drug: SCFA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCFA treatment (100 mL, twice daily enemas of sodium acetate 80 mmol/L, sodium propionate 30 mmol/L and sodium butyrate 40 mmol/L)
Study: 7654893
Drug: SCFA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCFA treatment
Study: 29223437
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with or without GPI
Study: 15870629
Drug: NaHCO3 ingestion
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaHCO3 ingestion (0.2 g x kg(‐1))
Study: 15870629
Drug: NaCl (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (placebo, 0.138 g x kg(‐1))
Study: 12049015
Drug: Epidural Ropivacain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Ropivacain (R) infusion
Study: 12049015
Drug: Epidural Bupivacain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Bupivacain (B) infusion
Study: 10613613
Drug: Dextromethorphan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (80 mg)
Study: 10613613
Drug: Chloroguanide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroguanide (200 mg)
Study: 7778068
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg subcutaneous
Study: 7778068
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg subcutaneous
Study: 7778068
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg intravenous
Study: 6999545
Drug: Naproxen tablets
Normalized name: Naproxen Tablets
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen tablets
Study: 356764
Drug: Naproxen suppositories
Normalized name: naproxen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen suppositories
Study: 21375606
Drug: Five-grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-grass pollen sublingual immunotherapy tablets
Study: 17709354
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A received routine postoperative advice and a three-day prescription of paracetamol, ibuprofen, and codeine.
Study: 11979408
Drug: Complicated appendicitis
Normalized name: AVOBENZONE 3 g in 100 g / HOMOSALATE 10 g in 100 g / OCTISALATE 5 g in 100 g / OCTOCRYLENE 10 g in 100 g / OXYBENZONE 5 g in 100 g TOPICAL AEROSOL, SPRAY [UNCOMPLIKATED MAKEUP SETTING SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complicated appendicitis treatment
Study: 8109489
Drug: Corticosteroid pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid pretreatment (32-mg oral dose of methylprednisolone administered 6-24 hr before and again 2 hr before injection)
Study: 8109489
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered in the same time periods)
Study: 1095631
Drug: Papaverine hydrochloride
Normalized name: Papaverine Hydrochloride
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Papaverine hydrochloride (300 mg)
Study: 29016336
Drug: Mebendazole (MBZ)
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole (MBZ) 500 mg chewable tablet
Study: 21816977
Drug: Intensive multifactorial
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multifactorial treatment (IT)
Study: 24377409
Drug: Psychoanalytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytic therapy (average of 97 sessions, range: 25-205)
Study: 24377409
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control group (minimal treatment)
Study: 19568355
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg triamcinolone acetonide
Study: 19568355
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg triamcinolone acetonide
Study: 19568355
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg triamcinolone acetonide
Study: 15755868
Drug: HRT-EVP (sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT-EVP (sequential estradiol valerate plus progestin)
Study: 10656038
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral penicillin
Study: 10656038
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg DEC/kg
Study: 10656038
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral penicillin plus 1 mg DEC/kg
Study: 10656038
Drug: local antibiotics
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: local antibiotics
Study: 8521712
Drug: Continuous levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous levonorgestrel treatment with subdermal implants (Norplant)
Study: 2245269
Drug: Treatment during
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment during the Sheffield Psychotherapy Project
Study: 2245269
Drug: Exploratory therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exploratory therapies
Study: 17122090
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (100 mg)
Study: 27356530
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg soft gelatin capsule (marketed formulation)
Study: 27356530
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg hard gelatin capsule
Study: 27356530
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg soft gelatin capsules with 300 mg MDC8
Study: 27356530
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg soft gelatin capsules with 100 mg MDC8
Study: 20092962
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy and radiotherapy (CRT)
Study: 15837357
Drug: Oral chloramphenicol
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chloramphenicol (50mg/kg/day in four divided doses for 14 days)
Study: 15837357
Drug: Ofloxacin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (15 mg/kg/day in two divided doses for 3 days)
Study: 12028688
Drug: Dipyridamole (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (750 mg)
Study: 1918724
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 1.2 mg per day
Study: 1918724
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 2.4 mg per day
Study: 1918724
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing schedule
Study: 22093134
Drug: Valganciclovir (VGV)
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Valganciclovir (VGV) 900 mg b.i.d. for 7 days followed by 900 mg daily for up to 21 days
Study: 22093134
Drug: Ganciclovir (GCV)
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir (GCV) 5 mg/kg b.i.d. for 7 days followed by daily GCV 5 mg/kg for up to 21 days
Study: 15089791
Drug: Structured Treatment
Normalized name: Lipid,structured (From Sunflower Oil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Treatment and Teaching Programme (STTP) combining dietary freedom with insulin adjustment
Study: 15089791
Drug: Current standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard practice for treatment of Type 1 diabetes
Study: 12547241
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose complex therapy
Study: 12547241
Drug: Parenteral iron
Normalized name: Iron, parenteral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral iron administration
Study: 7662901
Drug: L‐NAME (NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NAME (NO synthase inhibitor) at doses of 40 micrograms kg‐1 injected plus 50 micrograms kg‐1 infused i.v.
Study: 7662901
Drug: Thyrotropin releasing
Normalized name: Thyrotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin releasing hormone (TRH) 200 micrograms i.v.
Study: 30270800
Drug: Aminophylline 250
Normalized name: aminophylline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 250 mg intravenously
Study: 14509461
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac 0.5%
Study: 16527227
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin 0.1%
Study: 16527227
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (ketorolac, indomethacin, artificial tears)
Study: 10371400
Drug: Ethanol 0.0
Normalized name: ethanol 0.05 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.0 g/kg (Control)
Study: 8660070
Drug: Intensive induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive induction therapy with additional intensification treatment (two blocks of intensification)
Study: 8660070
Drug: No intensification
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intensification treatment
Study: 8660070
Drug: Intensive induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive induction therapy
Study: 8660070
Drug: Intensification treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification treatment
Study: 1997060
Drug: Propofol as
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol as an anaesthetic induction agent
Study: 30670282
Drug: Complementary medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary medicine (CAM) use
Study: 25792086
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate 5 g b.i.d. and CoQ10 100 mg t.i.d. orally
Study: 11464149
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of basic vaccine trial concepts
Study: 26643109
Drug: Eviprostat (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eviprostat (two capsules, q 8 h) for 8 weeks